Versartis, Inc. (VSAR) - NASDAQ
  • Thu, Apr. 28, 5:07 PM
    | Thu, Apr. 28, 5:07 PM
  • Fri, Feb. 19, 10:02 AM
    • Versartis (VSAR -3.2%) Q4 results: Revenues: $0; R&D Expense: $15.6M (+34.5%); SG&A: $4.6M (+7.0%); Operating Loss: ($20.2M) (-27.0%); Net Loss: ($20.1M) (-28.0%); Loss Per Share: ($0.69) (-6.2%).
    • FY2015 results: Revenues: $0; R&D Expense: $60M (+84.0%); SG&A: $22.5M (+66.7%); Operating Loss: ($82.5M) (-79.0%); Net Loss: ($82.2M) (+1.1%); Loss Per Share: ($2.84) (+35.3%); Quick Assets: $182.1M (+6.7%).
    • No guidance given.
    | Fri, Feb. 19, 10:02 AM
  • Thu, Feb. 18, 4:44 PM
    | Thu, Feb. 18, 4:44 PM
  • Oct. 29, 2015, 5:19 PM
    • Versartis (NASDAQ:VSAR): Q3 EPS of -$0.69 beats by $0.02.
    • PR
    | Oct. 29, 2015, 5:19 PM
  • Aug. 4, 2015, 8:35 AM
    • Versartis (NASDAQ:VSAR): Q2 EPS of -$0.67 misses by $0.03.
    | Aug. 4, 2015, 8:35 AM
  • May 6, 2015, 6:06 PM
    • Versartis (NASDAQ:VSAR): Q1 EPS of -$0.79 misses by $0.16.
    | May 6, 2015, 6:06 PM
  • Feb. 12, 2015, 5:05 PM
    • Versartis (NASDAQ:VSAR): Q4 EPS of -$0.65 misses by $0.21.
    | Feb. 12, 2015, 5:05 PM
  • Nov. 6, 2014, 6:07 PM
    • Versartis (NASDAQ:VSAR): Q3 EPS of -$0.57 misses by $0.04.
    | Nov. 6, 2014, 6:07 PM
  • Aug. 5, 2014, 6:15 PM
    • Versartis (NASDAQ:VSAR): Q2 EPS of -$0.36 beats by $0.09.
    | Aug. 5, 2014, 6:15 PM
  • Aug. 5, 2014, 4:40 PM
    • Versartis (VSAR -4%) Q2 results: Revenues: $0; Operating Expenses: $8.5M (+113.4%); Operating Loss: ($8.5M) (-113.4%); Net Loss: ($8.6M) (-135.3%); Loss Per Share: ($0.36) (+98.5%); Quick Assets: $192.8M (+999%).
    • No guidance given.
    | Aug. 5, 2014, 4:40 PM
Company Description
Versartis, Inc. is an endocrine-focused biopharmaceutical company. It develops long-acting therapeutic proteins for the treatment of endocrine disorders. The company develops new therapeutic proteins utilizing the novel half-life extension technology XTEN. Versartis was founded by Jeffrey L.... More
Sector: Healthcare
Industry: Drugs - Generic
Country: United States